U.S. markets close in 6 hours 16 minutes
  • S&P 500

    4,266.76
    +24.92 (+0.59%)
     
  • Dow 30

    34,144.31
    +270.07 (+0.80%)
     
  • Nasdaq

    14,379.23
    +107.50 (+0.75%)
     
  • Russell 2000

    2,303.47
    +7.52 (+0.33%)
     
  • Crude Oil

    72.61
    -0.47 (-0.64%)
     
  • Gold

    1,784.20
    +0.80 (+0.04%)
     
  • Silver

    26.17
    +0.05 (+0.21%)
     
  • EUR/USD

    1.1956
    +0.0023 (+0.19%)
     
  • 10-Yr Bond

    1.4900
    +0.0030 (+0.20%)
     
  • GBP/USD

    1.3929
    -0.0035 (-0.25%)
     
  • USD/JPY

    110.7620
    -0.2000 (-0.18%)
     
  • BTC-USD

    33,982.01
    -181.72 (-0.53%)
     
  • CMC Crypto 200

    818.63
    +32.01 (+4.07%)
     
  • FTSE 100

    7,108.18
    +34.12 (+0.48%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Xencor to Present at the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. ET / 10:00 a.m. PT.

A webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005825/en/

Contacts

Charles Liles
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com